<DOC>
	<DOCNO>NCT01910597</DOCNO>
	<brief_summary>Soluble Beta-Glucan ( SBG ) compound prepare commercial active dry Baker 's yeast proceed multi-step laboratory process invent Prof. Rapepun Wititsuwannakul , Faculty Science , Prince Songkla University , Thailand . Based upon pre-clinical data , SBG show inhibit angiogenesis probably enhance immune function , leading shrinkage tumor size athymic nude mouse inject hepatocellular carcinoma cell ( HepG2 ) cervical cancer cell . Therefore , investigator expect see safety anti-cancer property SBG patient advance cancer available therapy offer .</brief_summary>
	<brief_title>Phase I , Dose-Escalation Study Soluble Beta-Glucan ( SBG ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis histologically cytologically document , advancedstage , primary metastatic solid tumor refractory standard therapy available standard therapy exists . Evidence measurable evaluable disease . Age must least 18 year . ECOG performance status must 0 2 . Received best supportive care . Patient must meet protocolspecified laboratory value . Second primary cancer diagnose within 5 year , except cervical carcinoma situ , basal cell carcinoma squamous cell carcinoma complete curative treatment . Concurrent therapy investigational agent . Severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation studydrug administration may interfere interpretation study result , judgment investigator , make subject inappropriate study . Allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>